1450-76-6

Basic information

• Product Name: 2'-HYDROXY-5'-NITROACETOPHENONE
• Synonyms: 2'-HYDROXY-5'-NITROACETOPHENONE;2-HYDROXY-5-NITROACETOPHENONE;1-(2-HYDROXY-5-NITROPHENYL)ETHANONE;1-(5-Nitro-2-hydroxyphenyl)ethanone;Nsc64461;1-(2-hydroxy-5-nitrophenyl)ethan-1-one;2'-Hydroxy-5'-nitroacetophenone 97%;Ethanone, 1-(2-hydroxy-5-nitrophenyl)-
• CAS NO: 1450-76-6
• Molecular Formula: C₈H₇NO₄
• Molecular Weight: 181.14548
• Product Categories: Benzene series;Alcohols and Derivatives;Carbonyl Compounds;Aromatic Acetophenones & Derivatives (substituted);C7 to C8;Carbonyl Compounds;Ketones
• Mol File: 1450-76-6.mol
• Article Data: 29

Chemical Properties

• Melting Point: 100-104 °C(lit.)
• Boiling Point: 285.5 °C at 760 mmHg
• Flash Point: 126 °C
• Appearance: /
• Density: 1.38 g/cm³
• Vapor Pressure: 0.00163mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Methanol (Slightly, Heated)
• PKA: 7.27±0.22(Predicted)
• CAS DataBase Reference: 2'-HYDROXY-5'-NITROACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-HYDROXY-5'-NITROACETOPHENONE(1450-76-6)
• EPA Substance Registry System: 2'-HYDROXY-5'-NITROACETOPHENONE(1450-76-6)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1450-76-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1450-76-6 differently. You can refer to the following data:
1. 2’hydroxy-5’acetophenone is a potential inhibitor of platelet aggregation.
2. 2’-hydroxy-5’-acetophenone is a potential inhibitor of platelet aggregation.

InChI:InChI=1/C8H7NO4/c1-5(10)7-4-6(9(12)13)2-3-8(7)11/h2-4,11H,1H3/p-1

Upstream product

• 51484-05-0 6-nitro-chromen-4-one 
• 100-02-7 4-nitro-phenol 
• 108-24-7 acetic anhydride 
• 118-93-4 o-hydroxyacetophenone 
• 830-03-5 4-nitrophenol acetate 
• 75-36-5 acetyl chloride 
• 14150-94-8 3,5-dinitro-1-methyl-2-pyridone 
• 15435-71-9 sodium acetylacetonate 
• 10320-42-0 2-Chloro-5-nitropyrimidine 
• 123-54-6 acetylacetone 
• 14001-69-5 5-nitro-2-methoxypyrimidine 
• 68541-87-7 1-(2-methyl-5-nitropyridin-3-yl)ethanone 
• 100-17-4 para-methoxynitrobenzene 
• 64-19-7 acetic acid 

Downstream Products

• 3316-09-4 1,2-dihydroxy-4-nitrobenzene 
• 35234-45-8 (E)-1-(2-hydroxy-5-nitrophenyl)-3-phenylprop-2-en-1-one 
• 1776-26-7 2'-hydroxy-4-methoxy-5'-nitro-trans-chalcone 
• 133043-99-9 5-bromo-2'-hydroxy-2-methoxy-5'-nitro-trans-chalcone 
• 111439-48-6 3-benzoyl-6-nitro-2-phenyl-chromen-4-one 
• 61941-46-6 1-(2-methoxy-5-nitro-phenyl)-ethanone 
• 1776-27-8 2'-hydroxy-2,5'-dinitro-trans-chalcone 
• 18791-83-8 (E)-3-(4-Bromo-thiophen-2-yl)-1-(2-hydroxy-5-nitro-phenyl)-propenone 
• 76988-07-3 2-Hydroxy-5-nitro-ω-thiophenylideneacetophenone 
• 118761-30-1 1-(2-hydroxy-5-nitrophenyl)-3-(3-thienyl)-2-propen-1-one 
• 87699-35-2 1-(2-{2-[Bis-(2-chloro-ethyl)-amino]-ethoxy}-5-nitro-phenyl)-ethanone; hydrochloride 
• 87699-37-4 1-(2-{2-[[2-(2-Acetyl-4-nitro-phenoxy)-ethyl]-(2-chloro-ethyl)-amino]-ethoxy}-5-nitro-phenyl)-ethanone; hydrochloride 
• 97481-55-5 6-Amino-5-[1-(2-hydroxy-5-nitro-phenyl)-eth-(E)-ylideneamino]-1,3-dimethyl-1H-pyrimidine-2,4-dione 
• 88521-72-6 ethyl 2-acetyl-4-nitrophenoxyacetate 

Relevant articles and documents

A new and improved process for celiprolol hydrochloride

Celiprolol hydrochloride, a β-blocker drug, has been synthesized by a new approach. How this new process offers distinctive advantages over the existing one will be described.

Sigma Complexes in the Pyrimidine Series. 6. Reaction of 5-Nitro-2-methoxy- and 5-Nitro-4,6-dimethoxypyrimidines with the Acetylacetone Carbanion

Depending on the reaction conditions, the reaction of 5-nitro-2-methoxy- and 5-nitro-4,6-dimethoxypyrimidines with acetylacetone carbanion gives potassium salts of 5-nitrodiacetylmethylenepyrimidines or, as a result of recyclization of the pyrimidine ring, 5-nitro-2-hydroxyacetophenone.

Raf kinase inhibitor based on chromone structure, and preparation method and uses thereof

The invention relates to the technical field of pharmaceutical chemistry, and more concretely relates to a group of chromone compounds (A), wherein R1-R10, X1 and X2 are defined in the description. The invention also discloses a preparation method of the

Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors

Two series of thienopyrimidine derivatives (10a-k, 16a-j) bearing chromone moiety were designed and synthesized. All the compounds were evaluated for inhibitory activity against mTOR kinase at a concentration of 10uM. Four selected compounds were further evaluated for the IC50 values against mTOR kinase, PI3Kα kinase and two cancer cell lines. Some of the target compounds exhibited moderate to excellent mTOR/PI3Kα kinase inhibitory activity and cytotoxicity. The most promising compound 16i showed good inhibitory activity against mTOR/PI3Kα kinase and good antitumor potency for H460 and PC-3 cell lines with IC50 values of 0.16 ± 0.03 μM, 2.35 ± 0.19 μM, 1.20 ± 0.23 μM and 0.85 ± 0.04 μM, which were 8.6, >5, 7.9 and 19.1 times more active than compound I (1.37 ± 0.07 μM, >10 μM, 9.52 ± 0.29 μM, 16.27 ± 0.54 μM), respectively. Structure-activity relationships (SARs) and docking studies indicated that the chromone moiety is necessary for the potent antitumor activity and cytotoxicity of these compounds. Substitution of the chromone moiety at the 6-position has a significant impact to the inhibitory activity, in particular a carboxylic acid group, produced the best potency.